期刊文献+

体外膀胱灌注噻替哌和丝裂霉素C的药效学研究 被引量:3

A pharmacodynamic study of thiotepa and mitomycin C on human bladder cancer cell line in vitro
原文传递
导出
摘要 目的 探讨体外膀胱灌注噻替哌和丝裂霉素C 药物浓度和作用时间对膀胱癌细胞杀伤作用的影响。 方法 用不同浓度的抗肿瘤药物与人膀胱移行细胞癌细胞系BIU87 共同培养至一定时间,采用MTT 比色法测定细胞存活率。 结果 细胞存活率与二药的药物浓度和作用时间均呈明显的线性相关( P< 0 .01) ,而且主要与浓度有关;当超过一定作用时间后,存活率仅与药物浓度呈负相关( P< 0 .01) 。 结论 只有保证有效的作用时间,尽量增加药物剂量和有效浓度,才能显著提高膀胱腔内化疗效果,减少复发。 Objective To study the cytotoxic effect of thiotepa (THT) and mitomycin C (MMC) on human bladder cancer cell line in vitro. Methods Human bladder transitional cell carcinoma cell line BIU 87 was cultured for varying period with varying concentrations of the antineoplastic agents added.MTT colorimetric assay was used to determine the cell survival rate. Results Drug concentration and exposure period were significantly correlated with the cell survival rate ( P <0.01),drug concentration being the predominant.When the effective exposure period for the drugs was ensured and accessed the cell survival rate was only negatively correlated with drug concentration ( P <0.01). Conclusions When the effective exposure period is guarranted,increase of drug dose and the effective concentration would significantly enhance the therapeutic effect of the intravesical chemotherapy,thus reducing the recuurence rate of bladder cancer after surgical management.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 1999年第10期616-618,共3页 Chinese Journal of Urology
关键词 膀胱肿瘤 噻替哌 丝裂霉素C 药效学 体外灌注 Bladder neoplasms Carcinoma Perfusion
  • 相关文献

参考文献2

  • 1俞莉章 黄雅丽 等.人体膀胱行细胞癌细胞系BIU-87的建立及其生物学特性[J].中华泌尿外科杂志,1989,10:131-135.
  • 2俞莉章,中华泌尿外科杂志,1989年,10卷,131页

同被引文献11

  • 1沈周俊,丁国庆,吴金艳,余燕岚,陆静,陈善闻,陈军.膀胱内灌注纤维蛋白溶解抑制药物对卡介苗抗膀胱癌复发作用影响的临床研究[J].中华泌尿外科杂志,2006,27(1):25-28. 被引量:6
  • 2兰卫华,靳风烁,王洛夫,张军,孙中义,谢芳.卡介苗与丝裂霉素C膀胱灌注预防国人膀胱癌复发的比较的Meta分析[J].临床泌尿外科杂志,2006,21(2):145-148. 被引量:10
  • 3Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer [J]. Eur Urol, 2002, 41(2) :105-112.
  • 4Clarke NS, Basu S, Prescott S, et al. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists [J]. BJU Int, 2006, 97(4) :716- 719.
  • 5Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer [J]. Cancer Chemother Pharmacol, 1993, 32(4) :255-262.
  • 6Chopin DK, Cattegno B. Superficial bladder tumors [J]. Eur Urol, 2002, 42(2):533-541.
  • 7Bouffioux C, Kurth K, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma~ results of EORTC randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short - term versus long-term treatment [J]. J Urol, 1995, 153(3 pt 2): 934-941.
  • 8Fukui I, Kihara K, Sekine H, et al. Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response[J]. Cancer Chemother Pharmacol, 1992, 30(Suppl):37-40.
  • 9L. T. M. Balemans,P. D. J. Vegt,P. A. Steerenberg,E. C. Boer,A. Swaaij,R. E. M. Vries,A. P. M. Meijden,W. Otter. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder[J] 1994,Urological Research(4):239~245
  • 10叶敏,舒畅,马邦一,陈建华,张良.吡柔比星诱导膀胱癌细胞凋亡的实验研究及预防膀胱癌术后复发的效果[J].中华泌尿外科杂志,2002,23(1):16-18. 被引量:157

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部